Compound comparison · Metabolic research
Retatrutide vs Tirzepatide
Retatrutide is a triple receptor agonist under investigation; tirzepatide is a dual receptor agonist with an established clinical evidence base. Their results come from different study populations and protocols.
Side-by-side research overview
Research areaRetatrutideTirzepatide
Receptor targetsRetatrutideGLP-1, GIP, glucagonTirzepatideGLP-1, GIP
Research statusRetatrutideInvestigational compoundTirzepatideApproved medicines exist in some markets; research vials are not approved medicines
EvidenceRetatrutidePhase II and Phase III clinical researchTirzepatideLarge Phase III trial programme and post-approval evidence
Do not compare outcomes across separate trials as if they were a head-to-head result. Trial populations, doses and follow-up periods differ. These catalogue items are for research only, not for human consumption or medical treatment.
Explore each compound
Questions about research vials?
Check the exact product, dosage and lot records before you order. Our team can confirm current availability and delivery for your Bali address.
Ask on WhatsApp